Liver and other toxicities threaten to scupper another attempt to reactivate mutated p53, the “guardian of the genome”.
June will see adcoms aplenty, with Bluebird, Acadia, and the Covid vaccine makers Novavax, Pfizer/Biontech and Moderna all facing FDA committees.
New extended consensus forecasts from Evaluate Pharma show Roche edged out of first place by Abbvie as new blood replaces Humira.
Biopharma is approaching the most painful period of patent loss for at least 30 years. Is M&A an answer?